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AbstrAct
Objectives Inaccurate antibiotic dosing can lead to 
treatment failure, fuel antimicrobial resistance and 
increase side effects. The British National Formulary for 
Children (BNFC) guidance recommends oral antibiotic 
dosing according to age bands as a proxy for weight. 
Recommended doses of amoxicillin for children were 
increased in 2014 ‘after widespread concerns of under 
dosing’. However, the impact of dose changes on British 
children of different weights is unknown, particularly given 
the rising prevalence of childhood obesity in the UK. We 
aimed to estimate the accuracy of oral amoxicillin dosing 
in British children before and after the revised BNFC 
guidance in 2014.
setting and participants We used data on age and 
weights for 1556 British children (aged 2–18 years) from a 
nationally representative cross-sectional survey, the Health 
Survey for England 2013.
Interventions We calculated the doses each child would 
receive using the BNFC age band guidance, before and 
after the 2014 changes, against the ‘gold standard’ 
weight-based dose of amoxicillin, as per its summary of 
product characteristics.
Primary outcome measure Assuming children of 
different weights were equally likely to receive antibiotics, 
we calculated the percentage of the children who would 
be at risk of misdosing by the BNFC age bands.
results Before 2014, 54.6% of children receiving oral 
amoxicillin would have been underdosed and no child 
would have received more than the recommended dose. 
After the BNFC guidance changed in 2014, the number of 
children estimated as underdosed dropped to 5.8%, but 
0.5% of the children would have received too high a dose.
conclusions Changes to the BNFC age-banded 
amoxicillin doses in 2014 have significantly reduced the 
proportion of children who are likely to be underdosed, 
with only a minimal rise in the number of those above the 
recommended range.
bAckgrOund
Over a third of British children receive an 
antibiotic each year, and more than half of 
these are oral penicillins, most frequently 
for otitis media, symptoms of sore throat 
and cough.1–3 The majority of antibiotic 
prescriptions are unnecessary given that most 
infectious illnesses are viral or have a low risk-
to-benefit ratio,4 5 but when they are required 
it is important they are dosed appropriately. 
Inaccurate dosing of antibiotics may expose 
children to iatrogenic harm. Subtherapeutic 
antibiotic dosing can lead to treatment failure 
and fuel antimicrobial resistance, while exces-
sive doses could increase the incidence and 
severity of side effects and toxicity.6 7 Paedi-
atric drug dosing is more complex than in 
adults and should ideally reflect the age 
and weight of the child. The age-banding 
system used for prescribing paediatric oral 
antibiotics in the UK has the benefits of not 
requiring an up-to-date weight on the child 
and streamlines prescriptions to avoid more 
error-prone drug measurements.8 However, 
given that the weights of children do not 
change in a linear fashion with age, the UK’s 
age-banding system is more likely to result 
in suboptimal dosing than in continental 
Europe, where prescriptions are typically 
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strengths and limitaions of this study
 ► Strengths of this study are that this is the first study 
to evaluate this major change in children’s antibiotic 
dosing guidance in Britain.
 ► Use of a large nationally representative sample of 
the UK child population.
 ► Limitations of this study are that there was no data 
for children under 2 years of age.
 ► Assumption that all children are equally likely to be 
prescribed antibiotics.
 ► Assumption that clinicians are adhering to the 
guidelines.
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Table 1 British National Formulary for Children (BNFC) oral amoxicillin doses before and after 2014 guidance change
Paediatric oral amoxicillin dosing—standard dose
Pre-BNFC 2014 change: BNFC 2013–2014 Post-BNFC 2014 change: BNFC 2014–2015
Age Three times daily dose Age Three times daily dose
<1 month 30 mg/kg <1 month 30 mg/kg
1 month–1 year 62.5 mg 1 month–1 year 125 mg
1 year–5 years 125 mg 1 year–5 years 250 mg
5 years–18 years 250 mg 5 years–12 years 500 mg
12 years–18 years 500 mg
Table 2 Dosing limits of amoxicillin defined by the 
summary of product characteristics13
Amoxicillin paediatric dosing range
Lower limit Upper limit
Children <40 kg 40 mg/kg/day 90 mg/kg/day
(not exceeding 3 g/
day)
Children >40 kg ‘As per Adult 
dosing’: 
standard lower limit 
750 mg/day
‘As per Adult dosing’:
standard maximum is 
3 g/day
calculated according to weight (ie, milligrams per kilo-
gram per dose).8 This is further complicated because the 
few original pharmacokinetic and pharmacodynamics 
studies predate rising trends for obesity in children.8–10
A relatively arbitrary principle of halving adult oral 
penicillin doses for older children and again for younger 
children to infants was initially applied in the 1960s.11 
Amoxicillin bands, which were originally published in the 
1976–1978 British National Formulary, the main refer-
ence source for drug prescribing in the UK, remained in 
place for many years and were generally not questioned 
until 2011.10 In 2014, the British National Formulary for 
Children (BNFC) changed its amoxicillin age-banded 
doses for children to ‘come in line with European recom-
mendations after widespread concerns of under dosing’ were 
reported in children receiving amoxicillin in primary 
care.6 Current guidelines still recommend age bands, 
with dosing increased if necessary up to 30 mg/kg three 
times a day. Three times daily dosing is favoured due to 
the short half-life of amoxicillin. The dose for each age 
band has been doubled, when compared with the former 
standard dose for all age groups (table 1).
Despite the changes, previous simulations have shown 
up to 18% of British children admitted to hospital would 
receive amoxicillin doses outside the recommended 
guidance when age bands are used.8 However, children 
admitted to hospital may have a different distribution of 
weight compared with those in the community, one in 
three of whom is overweight by the age of 11 years. In this 
study, we aimed to evaluate the impact of this guidance 
change by estimating the percentage of British children 
receiving too high or too low a dose of oral amoxicillin 
according to their weights before and after changes to the 
BNFC in 2014.
MethOds
Although electronic records are available in primary 
care detailing drug doses, there is no systematic weight 
monitoring at or near the time of drug prescribing for 
children. Therefore we estimated the dose of amoxicillin 
a child would have received both before and after the 
BNFC 2014 guidance change using a nationally represen-
tative cross-sectional survey of British children’s weights. 
We used data on age and weights for 1556 British children 
(aged 2–18 years) from the most recent Health Survey 
for England 2013 (HSE 2013).12 We assumed that the 
BNFC guidance is followed and that children of different 
weights and ages were equally likely to receive antibiotics, 
and then estimated the doses each child would receive 
using the BNFC age band guidance, before and after the 
2014 changes (see table 1). We compared these against 
an assumed ‘gold standard’ of weight-based dosing for 
amoxicillin13 (see table 2). Our main outcome was the 
risk of underdose or overdose, defined as the percentage 
of children who would theoretically receive a dose outside 
the suggested summary of product characteristics’ (SPC) 
limits.13
To allow comparisons across age categories that slightly 
differed between 2013/2014 and 2014/2015 BNFC guid-
ance, we included children up to their fifth birthday in 
the category of children aged 1–5 years old (table 1). 
We were unable to examine impact of dosing changes in 
infants using these data because the HSE includes only 
children aged 2 years and above. We analysed the statis-
tical significance of the change in risk of underdosing or 
overdosing using Χ2 tests. We performed these analyses 
among the population overall, as well as individually for 
children above and below the 40 kg cut-off.
results
The HSE 2013 had data on age and weights for 1556 chil-
dren aged 2–18 years old. Of these 881 (56%) weighed 
less than 40 kg and 675 (43%) were over 40 kg. We esti-
mated that before the BNFC guidance change, 850 
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(54.6%) of children receiving oral amoxicillin would 
have been underdosed. After the guidance changed, 
this number fell to 91 (5.8%) (p<0.001). Prior to 2014, 
none of the children would have received more than the 
recommended dose, but after the guidance changed we 
estimated that eight (0.5%) of the children would have 
received too high a dose (p<0.001) (table 3). A sensitivity 
analysis showed that all these children were aged 5 years. 
Although the higher doses ranged from 2% to 14% above 
the recommended limit, only one of these children would 
have received an overdose of more than 10%.
The improvements in underdosing mainly benefited 
older children, whereas around one in three children 
aged 4 years was still likely to receive less than the recom-
mended dose (figure 1). Despite the change, 91 of 881 
(10.3%) children with a weight less than 40 kg were still 
underdosed after the guidance changed, but all 675 
children weighing over 40 kg in our sample received the 
correct dose after the changes.
dIscussIOn
Changes to the BNFC age-banded oral amoxicillin doses 
in 2014 have significantly increased the chances that chil-
dren will get the correct dose from 46% to 94%, dramat-
ically reducing the risk of underdosing in children. This 
is offset by only a very small rise in the number at risk 
of being dosed above the recommended range. Applying 
these percentages to current estimations on population 
size of the British birth cohort,14 approximately 7.5 million 
children and young people aged less than 18 years were 
at risk of being underdosed when prescribed oral amoxi-
cillin prior to the guidance change, which is now reduced 
to approximately 790 000. Against this, the revised guid-
ance puts approximately 68 000 children at increased risk 
of receiving a slightly higher dose (2%–14%) than the 
recommended limit for children, although there is little 
evidence to suggest this would be harmful.
strengths and weaknesses in relation to previous studies
Ours is the first study to evaluate a major change in chil-
dren’s antibiotic dosing guidance in Britain.
In using the latest HSE, we were able to estimate the 
theoretical impact of the guidance change on the most 
recent large nationally representative sample of the 
UK child population. Although good quality data on 
prescribing are available from within routine electronic 
records, there are currently no systematically recorded 
data on the weights of children taken around the time of 
prescribing antibiotics in primary care available to model 
and examine dosing accuracy. However there are signif-
icant challenges to measuring the impact of changes in 
drug dosing guidance in a large population that may limit 
the validity and generalisability of our findings.
First, these data only include children who are aged 
2 years or older. Children aged less than 2 years make 
up approximately 18.7%14 of the paediatric population, 
receiving a significant proportion of paediatric antibiotic 
prescriptions,15 and fall into the under 40 kg category, 
so are more likely to have been affected by the guid-
ance changes. Second, our estimations assumed that all 
children are equally likely to be prescribed antibiotics. 
However, incidence of acute bacterial infections is higher 
among preschool children, and there is some evidence 
that very underweight children (<3rd centile) may be at 
higher risk of such infections.16 17 Hence our estimation 
will overestimate ‘correct’ dosing for these groups.
A third source of error is using the SPC as a gold 
standard to provide the upper and lower boundaries 
of prescribing. Pharmacokinetic studies in children on 
which the ‘gold standard’ weight-based guidance is based 
are limited and may explain an internal inconsistency 
within the SPC. The minimum acceptable dose of oral 
amoxicillin for a child weighing between 18.75 kg and 
40 kg is higher than that accepted for an adult (because 
40 mg/kg/day is more than 750 mg at weights greater 
than 18.75 kg). There is evidence for aiming for higher 
doses within the 40–90 mg/kg/day range to treat acute 
otitis media in children,18 19 and this mismatch between 
acceptable levels in children and adult has previously 
been identified.20 Another example of this is that there 
appears to be a non-linear relationship of obesity and 
drug exposure21 that may be a source of bias in our 
estimations. Defining appropriate dosing is also condi-
tion-specific, something we have not accounted for, for 
example, with higher doses recommended in acute otitis 
media compared with pharyngitis.
Finally our estimations also assume that clinicians are 
following the guidelines. Previous research suggests this 
is not necessarily the case,6 but this has not been eval-
uated since the guidance change. Our pre-2014 guid-
ance change findings are consistent with Ahmed et al’s10 
calculations on average weights from HSE 2011, which 
suggested significant underdosing. Bielicki et al8 recently 
looked at the post-2014 BNFC guidance change for chil-
dren weighing less than 40 kg admitted to hospital. The 
rates for underdosing were similar (7% vs our 10.3%), but 
they found 11% of children to be receiving above recom-
mended doses compared with our study (0.9%). This may 
be explained by a sicker population of children seen in 
hospital compared with those treated in the community.
Implications and future research
Our findings suggest that the recent BNFC 2014 oral 
amoxicillin age band dosing changes will have resulted in 
more optimal prescribing. Although this is a significant 
improvement in favour of evidence-based prescribing, 
there may be a need to raise awareness among prescribers 
about these changes. Doing so may also provide a further 
opportunity for emphasising the need for judicious anti-
biotic use. What is not clear from this theoretical model is 
how these dosing variations impact on clinical outcomes. 
Answering this question poses significant methodolog-
ical challenges for research because many children are 
prescribed antibiotics who may not need them. Despite 
a substantial evidence base suggesting that penicillin has 
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Figure 1 Estimated proportion of inappropriate dosing of 
oral amoxicillin before and after the British National Formulary 
for Children (BNFC) guidance change in 2014, calculated 
using weights and ages of 1556 children from the Health 
Survey for England 2013.
limited benefits for acute sore throat, otitis media and 
other respiratory conditions in children,4 5 antibiotic 
prescribing in British primary care remains relatively 
high.22–24 Antibiotic prescribing in primary care also 
varies widely between physicians, who are not solely moti-
vated by a belief in drug efficacy. Patients’ expectations 
are sometimes cited as a reason for prescribing, under-
pinned by workload pressures, difficulties in doctor–
patient communication and diagnostic uncertainty.25 
More research may be useful to understand whether 
physicians prescribe differential doses according to their 
prescribing intention. Given the continued rise in child-
hood obesity, it may well be prudent to review other 
paediatric antibiotic guidelines accordingly. As well as the 
doses themselves, should we be questioning the dosing 
selection system: the appropriateness of the age-banding 
system versus a weight based system? The former enables 
simple prescribing with no need for an up-to-date weight 
but is risking increased dosing inaccuracy.8 We recom-
mend more studies are undertaken to examine the 
pharmacokinetics of antibiotics in overweight and under-
weight children.
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